Table 2.
Characteristics of patients (persistence analysis)
| Characteristics of the population (persistence study) Total 2011–2012 |
|
|---|---|
| Age (years) | N = 1969 |
| Mean ± SD | 66.4 (16.1) |
| Median [Range] | 68.0 [18.0; 101] |
| <40 | 145 (7.4%) |
| 40–50 | 157 (8.0%) |
| 50–60 | 306 (15.5%) |
| 60–70 | 453 (23.0%) |
| 70–80 | 423 (21.5%) |
| 80–90 | 417 (21.2%) |
| ≥90 | 68 (3.5%) |
| Gender | N = 1936 |
| Men | 1004 (51.9%) |
| Women | 932 (48.1%) |
| Initial insulin prescription | |
| Insulin only | 686 (34.8%) |
| Insulin + 1 OAD | 486 (24.7%) |
| Insulin + 2 OAD | 488 (24.8%) |
| Insulin + 3 OAD | 280 (14.2%) |
| Insulin + ≥ 4 OAD | 29 (1.5%) |
| Metformin | 896 (45.5%) |
| Sulphonylurea | 651 (33.1%) |
| α-Glucosidase inhibitor | 68 (3.5%) |
| Glinides | 295 (14.9%) |
| DPP4i | 399 (20.3%) |
| GLP-1 receptor agonists | 109 (5.5%) |
| Physician prescribing insulin | N = 1826 |
| Hospital physician | 728 (39.9%) |
| General practitioner | 796 (43.6%) |
| Community diabetologist | 297 (16.3%) |
| Other community specialist | 5 (0.3%) |
| Diabetes treatment before the insulin initiationa | N = 1969 |
| None | 526 (26.7%) |
| 1 OAD | 407 (20.7%) |
| 2 OAD | 511 (25.9%) |
| 3 OAD | 447 (22.7%) |
| ≥4 OAD | 8 (0.4%) |
SD standard deviation, OAD oral antidiabetic drug, DPP4i dipeptidyl peptidase inhibitor, GLP glucagon-like peptide, ND not determined
aOver the first or the second quarter before the initial insulin prescription